Apollo Health Ventures’ Post

📢𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗴𝗮𝗽 - 𝗔𝘂𝘀𝗕𝗶𝗼𝘁𝗲𝗰𝗵’𝘀 ‘𝗩𝗼𝗶𝗰𝗲 𝗼𝗻 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗦𝘂𝗿𝘃𝗲𝘆’ 𝟮𝟬𝟮𝟰     AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey. The Survey seeks critical member insights as AusBiotech builds a new strategies and programs to help bridge the gap between investor and company needs in the Australian biotech ecosystem. AusBiotech is considering new strategies to help bridge the gap between investor and company needs in the Australian biotech ecosystem. Our goal will be to enable greater synergies between these groups and help accelerate the path to commercialisation for our biotech and medtech members. We are now gathering insights to ensure this work is evidence led. If you are a biotech or medtech company leader who has sought, is seeking, or plan to seek investment, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗔𝘂𝘀𝗕𝗶𝗼𝘁𝗲𝗰𝗵’𝘀 ‘𝗩𝗼𝗶𝗰𝗲 𝗼𝗳 𝗙𝗼𝘂𝗻𝗱𝗲𝗿’ 𝘀𝘂𝗿𝘃𝗲𝘆 𝗯𝘆 𝟭𝟱𝘁𝗵 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 https://lnkd.in/d5q_aGH6 #AusBiotech #BiotechInvestment #AusBioInvest

Cicada Innovations is proud to be the operator of Jumar Bioincubator, working with esteemed partners CSL, WEHI (Walter and Eliza Hall Institute of Medical Research), and the University of Melbourne (UoM), as well as the Bioincunbator's initial investor Breakthrough Victoria. This opening presents opportunities to unite industry, research, and academia to accelerate Aussie biotech innovation for both Australia and the world. As commented by Cicada Innovations CEO Sally-Ann Williams FTSE, “In a decade to come… that’s when we need to be measuring impact. It’s not six months after something opens its doors. It’s, you know, five years, 10 years, 15 years from now...I’m hoping that in the decades to come, what we’ll be able to say is that the next global companies, biotech companies, were built, and they were residents of Jumar. Wouldn’t that be a phenomenal thing?” Let's continue to propel the power of deep tech innovation to create a healthier, more sustainable future. Read more about the official opening below ⬇️ https://shorturl.at/atx47 #JumarBioincubator #BiotechInnovation #AustralianBiotech #ResearchTranslation #BiotechStartups #DeepTech #DeepTechInnovation 

According to Robert Balfour, PhD of ALSA Ventures, the abundance of choices means longer wait times for funding rounds. But what sets a company apart? 🤔 Paola Pozzi from Soffinova Partners believes it's all about the science. A strong scientific foundation can significantly boost the value of initial public offerings (IPOs). 🚀 Exciting times for #pharma! The Advanced Therapies Conference 2024 shed light on the bustling year ahead for #biotech fundraising. With a crowded landscape, investors are taking their time to sift through numerous opportunities. 💼💡 Dominic O'Regan from New Mosaic Ltd emphasizes the importance of early-stage biotechs establishing clear asset positioning and future landscape fit. 🌐 Despite a dip in private biotech venture financing in 2023, there's a glimmer of hope. GlobalData's report suggests a potential shift in investor sentiment, with 44% of healthcare professionals feeling optimistic about biotech funding recovery in the next 12 months. 📈 Let's keep an eye on this dynamic sector as it navigates through challenges and opportunities. The key to success? Standout science and strategic clarity. #biotechfunding #investment #healthcareinnovation

One of the reasons that can explain the differences between the US and the EU is the complexity of market access in the EU. Intra-community harmonization is certainly necessary so that biotechs do not have the reflex to address the American market first!

This March, I'm speaking at Central European BioForum. Those who follow our Viseven journey probably know that in 2019, we took a great focus on global expansion. Ever since came riveting times of new challenges, lessons, failures, and successes. During the panel discussion "How to enter the US market?" I'll gladly share how Viseven managed the intricacies of this global expansion and cooperation with bio-related companies. #CEBioForum2024 is said to be the place where you meet key players in biotech in CEE in one spot in order to find business development opportunities. Together with Nataliya Kulyba, Maciej Najdzion, Oleksandra Yashyna (Zikh), and Dominika Sosnowska, we're looking forward to this opportunity. Meanwhile, let's connect! #martech #biotech #globalbusiness

Only 3 weeks until the 24th BioEquity Europe in San Sebastian, Spain. Please register now -- before it sells out! Partnering is open, 130+ biotechs confirmed to present, only a few slots left on our pre-event networking excursions (first-come, first-served). ✅ Register: https://lnkd.in/gSxxhu7 ✳️ One area to highlight -> This year's agenda focuses on: How can #biotechs "rise above the noise" to attract the right investors, partners and talent? Recent additions to the faculty, include: ➢ Arjen Lemmen of argenx ➢ Arno de Wilde of EQT Group ➢ Caroline Gaynor of Lightstone Ventures ➢ Christina Takke of V-Bio Ventures ➢ Claire Brown of Oxford Science Enterprises ➢ Dmitry 'Dima' Kuzmin of 4BIO Capital ➢ Elise Peters of Syncona Limited ➢ Florent Gros of Earlybird Venture Capital ➢ Franck Le Deu of McKinsey & Company ➢ Frank Kalkbrenner of Boehringer Ingelheim ➢ Jason P. Hafler of Sanofi ➢ Joep Muijrers of Gilde Healthcare ➢ Jonathan Tobin of Brandon Capital ➢ Karen Wagner of Ysios Capital ➢ Ksenija Pavletic of JEITO ➢ Nerida Scott of Johnson & Johnson ➢ Nina Rawal of Trill Impact ➢ Paulo Fontoura of Roche ➢ Dr. Shanshan Xu of BioNTech SE ➢ Søren Møller of Novo Nordisk And many more... I hope you will join BioCentury and EBD Group at this destination event for #biotech CEOs and investors. No event has a larger concentration of VCs than BioEquity. Please DM me if you have any questions. See you soon in San Sebastian! #venturecapital #drugdevelopment #biopharma #BioEquityEurope

Australia's biotech and health tech scene is a unique ecosystem, thriving with its own set of challenges and opportunities. Despite ranking as the fifth in the world for research and innovation, this sector often gets overshadowed by the more liquid software industry. With $1.2 billion invested, Australia's biotech is poised for a breakthroughbut it might just need a 'Canva moment' to truly soar. Join the conversation and explore the latest insights on the future of biotech innovation in Australia. #biotech #siliconvalley

🙏🏽𝗛𝘂𝗺𝗯𝗹𝗲 𝗠𝗼𝗺𝗲𝗻𝘁𝘀, 𝗕𝗶𝗴 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀. This morning, we woke up reflecting on an incredible journey. It’s been a path filled with challenges, growth, and determination. Today, with humility and a touch of pride, we are overjoyed to share that Biolevate has secured €𝟲 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝘀𝗲𝗲𝗱 𝗳𝘂𝗻𝗱𝗶𝗻𝗴. This milestone supports our mission to 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 by tackling one of the industry’s biggest challenges: medical writing. Our proprietary platform, 𝗘𝗟𝗜𝗦𝗘*, leverages advanced AI to transform the creation and management of regulatory and compliance documents, making processes faster, more accurate, and more collaborative. This milestone was made possible thanks to the trust of EQT Ventures, Bpifrance, and an inspiring group of angel investors who believe in our mission. 🧠 With the growing shortage of medical writers and the increasing demand for accurate documentation, our mission is to meet their needs in the marketplace. 🌟 𝗪𝗵𝘆 𝗘𝗟𝗜𝗦𝗘? 🔵 Real-time collaborative writing with instant compliance validation 🔵 Automated literature review and regulatory checks 🔵 Advanced analytics for risk assessment and anomaly detection This funding allows us to: ✅ 𝗘𝗻𝗵𝗮𝗻𝗰𝗲 𝗼𝘂𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺’𝘀 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 ✅ 𝗘𝘅𝗽𝗮𝗻𝗱 𝗼𝘂𝗿 𝘁𝗮𝗹𝗲𝗻𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 ✅ 𝗣𝘂𝘀𝗵 𝘁𝗵𝗲 𝗯𝗼𝘂𝗻𝗱𝗮𝗿𝗶𝗲𝘀 𝗼𝗳 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 💬 joel Belafa, CEO of Biolevate: "Artificial intelligence has immense potential. Our mission is to ensure patients receive life-saving treatments faster by optimizing medical writing and maintaining accuracy throughout the drug discovery process." 🫶𝗔 𝗵𝗲𝗮𝗿𝘁𝗳𝗲𝗹𝘁 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝘁𝗵𝗲 𝗕𝗶𝗼𝗹𝗲𝘃𝗮𝘁𝗲 𝘁𝗲𝗮𝗺! Tackling one of healthcare’s most pressing challenges—making research more efficient, compliant, and impactful—is no small feat. By maximizing the utilization of knowledge, you’re driving innovation and creating a brighter future for healthcare. Your dedication, expertise, and vision are truly inspiring. Together, you’re shaping a path where research translates into real-world impact, faster and smarter. Here’s to the continued success of this incredible journey. Thank you for everything you do! Thank you to everyone who has been part of this journey so far. This is just the beginning. 🚀 👉 Read more about our investment and Biolevate’s mission here: https://lnkd.in/eyi5fJ-X 👉🏽https://lnkd.in/eXvDVniZ ELISE 𝗘levate 𝗟𝗜fe Scienc𝗘* #AIinHealthcare #Innovation #MedTech #LifeSciences #FundingAnnouncement #RegulatoryCompliance #TeamBiolevate #InnovationInHealthcare #KnowledgeInAction

Attending #Bio Europe Spring again after some years has been inspiring. As former executive of a #Biotech company who now works as consultant for such companies, I enjoy learning about how much the Biotech environment has changed in #Europe and especially in #Spain. Six Spanish #Venturecapital entities organizing a joint together between companies and investors in globally is something that was a dream when I joined the sector in 2008. All of them are to be mentioned: Caixa Capital Risc, Asabys Partners, Invivo Partners, Ysios Capital, COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and Aliath Bioventures I had the possibility to listen to many intriguing presentations from a wide range of perspectives: my friend Jose Mesa from COLUMBUS VENTURE PARTNERS,Sc.G.E.I.C., S.A.U. talked about their social view translated into the Fundación Columbus for treating children with #rarediseases. Clara Campàs Moya from Asabys Partners explained their investment strategy and how the impact of investments are measured from an #ESG perspective. Laura A. Lane from Eli Lilly and Company provided colour on their three-pilar strategy for investment and Alain Huriez Hureiz from AdBio partners gave his view as a foreign #VentureCapital investing in Spain. Lubor Gaal and Philippe Lopes-Fernandes gave concise advice, stating “Do not do it because of fashion” or “If you want to codevelop with pharma companies, have clear goals for such a cooperation or you will fail.” What does the future of #Biotech hold? I don’t know, but I leave this conference with new ideas and a sense of excitement for what is to come. 

🎉 Biolibrary recently participated in FARETE 2024, an esteemed international business networking event organized by Confindustria Emilia Area Centro. This two-day event, held on September 4-5 at BolognaFiere Group, served as a vibrant platform where innovative companies, industry leaders, and potential investors converged 🤝. 🌱 At FARETE, we had the privilege of presenting Biolibrary's innovative biotechnology solutions and engaging in high-impact discussions with key stakeholders in the biotech industry. This platform, made possible by the support of Confindustria Emilia Area Centro, is vital for fostering growth, innovation, and strategic partnerships that shape the future of the sector. 🙏 We extend our heartfelt gratitude to Confindustria Emilia Area Centro and the FARETE organizing team for creating an invaluable platform for companies like ours to showcase their potential and connect with like-minded individuals and organizations. 💼 Investors, if you're looking to be part of a transformative journey in the biotech sector, we invite you to connect with us. Together, we can shape a future where innovation and investment thrive hand in hand 🌍. #Biolibrary #FARETE2024 #ConfindustriaEmiliaAreaCentro #BiotechnologyInvestment #InnovationInBiotech #SustainableBiotech #InvestInBiotech #Sustainability #Biotech #SAAS